Producer: LLC Pharm Start Ukraine
Code of automatic telephone exchange: N06BX23
Release form: Firm dosage forms. Capsules.
General characteristics. Structure:
Active agent: Phenibutum of 250 mg
Excipients: cellulose microcrystallic, sodium of a kroskarmelloz, silicon dioxide colloid anhydrous, magnesium stearate, talc; structure of the capsule: gelatin, titanium dioxide (E171).
Bifren — derivative GAMK and a feniletilamin. Its anti-hypoxemic and anti-anamnestic action is dominating. Has tranquilizing properties, stimulates memory and learnability, increases physical effeciency; eliminates psychoemotional tension, uneasiness, fear and improves a dream; extends and strengthens effect of hypnotic drugs, narcotic, antipsychotic and anticonvulsants. Does not influence on well-cared and adrenoceptors. Drug extends stage of latency and shortens duration and expressiveness of a nystagmus. Considerably reduces manifestations of an adynamy and vazovegetativny symptoms, including a headache, feeling of weight in the head, a sleep disorder, irritability, emotional lability, increases intellectual working capacity. Unlike tranquilizers under the influence of Bifren psychological indicators (attention, memory, speed and accuracy of sensory-motor reactions) improve. At patients with an adynamy and at emotionally labile patients from the first days of therapy by drug the health improves, interest and an initiative, motivation in vigorous activity without sedation or excitement increases. It is established that Bifren applied after a craniocereberal injury increases quantity of mitochondrions perifokalno and improves brain bio-energetics. In the presence of damages of heart and stomach Bifren normalizes processes of a peroksidation of lipids.
Drug is well soaked up after oral administration and well gets into all body tissues, well gets through GEB. Distribution in a liver and kidneys is close to uniform, and in a brain and blood — below uniform. In 3 h the noticeable quantity of the entered Phenibutum is defined in urine, in the same time concentration of drug in tissue of a brain does not go down, it is revealed in a brain in 6 h. Next day Phenibutum can be revealed only in urine; it is noted in urine in 2 days after reception, however this quantity makes only 5% of the entered dose. The greatest binding of Phenibutum happens in a liver (80%), it is not specific. At repeated introduction of cumulation it is not revealed.
Indications to use:
Decrease in intellectual and emotional activity, memory disturbance, decrease in concentration of attention. Asthenic and alarming and neurotic states, concern, fear, alarm, neurosis of persuasive states, psychopathy; children have a stutter, enuresis, tics; elderly people have a sleeplessness, night concern.
Prevention of stressful states, before operations or painful diagnostic testings.
Bifren apply as supportive application at treatment of alcoholism to the termination of psychopathological and somatovegetativny disturbances at an abstinence syndrome.
Drug can be used together with the standard disintoxication means for treatment of alcoholic predeliriozny and delirious states. Appoint also at Menyer's disease, dizzinesses connected with dysfunction of a vestibular mechanism for motion desease prevention. It is applied in complex treatment of women with osteochondrosis of cervicothoracic department of a backbone and climacteric frustration.
Route of administration and doses:
Inside before food, washing down with water.
The adult appoint 250–500 mg 3 times a day. The highest single doses: for adults — 750 mg, for patients are more senior than 60 years — 500 mg. The course of treatment makes 4–6 weeks.
To children aged from 11 years — on 250 mg 2–3 times a day.
Bifren it is possible to combine with other psychotropic drugs, it increases its efficiency. At the same time it is possible to lower Bifren's dose and other at the same time used drugs.
For stopping of an alcoholic abstinence syndrome Bifren in the first days of treatment appoint 250–500 mg 3 times a day and 750 mg to night with gradual decrease in a daily dose to usual for adults.
For elimination of dizziness at dysfunction of a vestibular mechanism of infectious genesis (an otogenic labyrinthitis) and Menyer's diseases in the period of an aggravation Bifren appoint 750 mg 3 times a day within 5–7 days, at reduction of expressiveness of vestibular frustration — on 250–500 mg 3 times a day within 5–7 days and then — on 250 mg of 1 times a day for 5 days. At rather easy course of diseases Bifren accept 250 mg 2 times a day within 5–7 days, and then — on 250 mg of 1 times a day within 7–10 days.
For elimination of dizziness at dysfunction of a vestibular mechanism of vascular and traumatic genesis Bifren appoint 250 mg 3 times a day for 12 days.
For prevention of a motion desease in the conditions of sea swimming appoint in a dose 250–500 mg once for an hour till the estimated beginning of rolling at emergence of the first symptoms of a sea sickness. Bifren's action amplifies at increase in a dose of drug. In the presence of the expressed displays of seasickness (vomiting, nausea) purpose of drug is ineffective even in a dose of 750-1000 mg.
For complex treatment of women with osteochondrosis of cervicothoracic department of a backbone and climacteric frustration appoint 250 mg 3 times a day during the first 2 weeks, in the following 2 weeks — on 250 mg 2 times a day. In case of moderate expressiveness of a vertebrogenny pain syndrome and climacteric frustration Bifren's use in a dose of 500 mg (250 mg 2 times a day) daily during 4 weeks of complex treatment of osteochondrosis is recommended.
If reception of one or several doses was missed, continue reception in earlier appointed doses, if necessary or at deterioration in health the patient should consult with the doctor.
Features of use:
It is necessary to be careful the patient with pathology of a digestive tract because of irritable effect of drug. This patient appoint drug in reduced doses. At prolonged use control cellular composition of blood, indicators of functional hepatic trials.
Use during pregnancy or feeding by a breast. Use of drug during pregnancy or feeding by a breast contraindicated as there are no sufficient data concerning use of drug during this period.
Ability to influence speed of response at control of vehicles or work with other mechanisms. Patients at whom during treatment by drug arise drowsiness, dizziness or other disturbances from TsNS should abstain from control of vehicles or work with other mechanisms.
Children. Drug can be used at children aged 11 years are more senior.
Interaction with other medicines:
Bifren it is possible to apply with other medicines, including with tranquilizers and neuroleptics as their effects can mutually amplify.
Bifren — low-toxic connection, only in a daily dose of 7-14 g at prolonged use he can be gepatotoksichny (noted an eosinophilia and fatty dystrophy of a liver).
Symptoms: drowsiness, nausea, vomiting, possible development of arterial hypotension, acute renal failure.
Treatment: gastric lavage. Therapy is symptomatic.
At complications (arterial hypotension, a renal failure) take auxiliary and symptomatic measures.
In original packaging at a temperature not above 25 °C.
According to the recipe
Капс. 250 mg blister, No. 20.